Add this topic to your myFT Digest for news straight to your inbox
Much will depend on drug trial data readouts in the second half of this year
Almost 40% of investors oppose the drugmaker’s pay report for 2016
Fund manager suffers 15th consecutive quarter of net outflows
Drug trial results will play a key role in recovery
Declines in Crestor and Nexium offset emerging markets growth
Protracted negotiations deny access to life-saving treatments, says Pascal Soriot
Success or failure of chief Pascal Soriot depends on drug discoveries
One-off tax gain helps cushion fall in earnings
Business leaders need to find what RSA chief Hester calls the ‘on-off switch’
As well as believing in a mission, people need to feel they contribute to getting closer to aims
Pharma group moves away from primary care towards more specialised lower-volume medicines
UK pharmaceuticals group to study results in detail in effort to expand use ahead of patent cliff
Sir Martin Sorrell will this week pocket the second-biggest pay cheque ever for a FTSE 100 boss
Drugmaker sells marketing rights for blood pressure and angina treatments for $500m
AstraZeneca and Shell chiefs take the stage, who gets applause?
UK drugmaker insists turnround is on track as it faces growing competition from generic medicines
Chief says progress in R&D and rising revenues justify Pfizer rejection
Loyalty, teamwork and courage are key to a man who fought his way out of the Paris suburbs
2016 will be critical for UK pharma groups’ divergent strategies
International Edition